Adjuvant therapy using <i>ex vivo</i>-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study
Jong Man Kim, Sung Yoo Cho, Jinsoo Rhu, Mi-Young Jung, Jung Hyun Her, Okjae Lim, Gyu‐Seong Choi, Eui‐Cheol Shin, Yu Kyeong Hwang, Jae‐Won Joh
Abstract
BACKGROUNDS/AIMS: -expanded allogenic natural killer (NK) cells in those patients with modified International Union Against Cancer (UICC) stage T3. METHODS: cells/kg) at postoperative 4, 6, 8, 12, and 16 weeks. This study is registered with ClinicalTrials.gov, number NCT02008929. RESULTS: -expanded allogenic NK cells compared with the three patients who experienced recurrence. CONCLUSIONS: -expanded allogenic NK cells in hepatectomy patients can be used safely. Further studies should be investigated for efficacy.
Topics & Concepts
MedicineEx vivoHepatocellular carcinomaGastroenterologyAdjuvant therapyHepatectomyImmunotherapyCD8Hepatitis B virusInternal medicineAdjuvantIn vivoLiver cancerCancerImmunologyOncologySurgeryImmune systemVirusResectionBiologyBiotechnologyImmune Cell Function and InteractionCancer Immunotherapy and BiomarkersHematopoietic Stem Cell Transplantation